ديجيتال فابلت

الوسم: personalized medicine

  • Insights from Eight Months of Tracking on Healthy Aging

    Insights from Eight Months of Tracking on Healthy Aging

    Most individuals learn about their health through occasional doctor visits and annual blood tests. While helpful, these snapshots only reflect the body’s state at a single moment in time.

    Researchers at the National University of Singapore are investigating an alternative approach: understanding health by observing daily changes and recovery patterns in the body.

    This project, known as DELTA, is highly personal. Professor Dean Ho, director of the Institute for Digital Medicine at the Yong Loo Lin School of Medicine, served as the sole participant.

    His team continuously monitored his body while he altered his diet, exercise routine, fasting periods, and sleep habits.

    The core idea of DELTA is that each person’s biological baseline isn’t static. Factors like sleep, stress, diet, physical activity, illness, and age can cause daily fluctuations in how the body functions. Even the same person might respond differently to the same challenge at different times.

    The study began in August 2024 and is ongoing. Over approximately eight months, Ho wore three consumer health devices—a Whoop tracker, a Garmin smartwatch, and an Apple Watch—which provided repeated data on heart rate, activity levels, recovery metrics, and sleep patterns.

    He also made significant lifestyle changes. Ho frequently fasted for about 20 hours daily and completed several 48-hour fasts. Each morning, he engaged in about 90 minutes of strength or cardio workouts.

    His diet centered on leafy greens, seeds, olive oil, lean proteins, and other foods typical of a Mediterranean diet. Beverage intake was mainly water, electrolytes, black coffee, and black tea—without milk or sugar. It’s important to note this was a personalized experiment, not a public health recommendation.

    A key focus was metabolic flexibility—the body’s ability to switch efficiently between using carbohydrates and fats for energy depending on fasting, activity, or food intake. Researchers tracked how quickly Ho transitioned from primarily burning sugar to relying on stored fat.

    Results showed his switching time improved during the study. Initially taking over 24 hours, it decreased to approximately 16.5 hours, indicating a more responsive metabolism.

    His resting heart rate also dropped significantly—from about 65 beats per minute to 46—suggesting enhanced cardiovascular fitness, though interpreting this value depends on individual health contexts, symptoms, and medications.

    Sleep patterns changed markedly. Ho shifted his bedtime from after midnight to around 9 p.m., with sleep duration increasing from roughly five hours to nearly eight, including more deep sleep and fewer nighttime awakenings.

    The team analyzed Ho’s gut microbiome—the community of microbes in his digestive system—and noted positive changes, such as the absence of Fusobacterium, a potentially harmful bacterium. The data also indicated shifts in how his body conserved energy during fasting periods.

    An AI system was employed to analyze the vast amount of data, acting as a health ‘copilot’ to assess how his body responded and recovered from stress. Remarkably, the system estimated his biological age to be around 32, even though he was 47.

    Biological age attempts to gauge how old the body appears based on measurable biological markers, not simply years since birth. Many such systems focus on a single set of blood, genetic, or physiological indicators. DELTA researchers emphasize that observing how quickly and effectively the body responds and recovers offers additional insights into healthy aging.

    This concept of resilience—how quickly and effectively one recovers from stress—is central to the project. Two people might have similar routine health estimates but react very differently to fasting, workouts, poor sleep, or illness. Measuring recovery speed and quality could reveal health information missed by standard annual exams.

    The findings were published in PLOS One, expanding on earlier research that appeared in PNAS Nexus in 2024. The researchers hope this approach will eventually enable individuals to utilize their personal long-term health data for more tailored health decisions, rather than following generic lifestyle advice.

    The project highlights how dense, continuous health monitoring can uncover subtle changes that routine health checks might miss. Tracking one individual repeatedly provides detailed insights, fostering new questions, measurement techniques, and technologies. It is particularly valuable as an exploratory tool.

    However, a major limitation is that the study involved only one person—who also happened to be the lead researcher. The results cannot be generalized to others, as responses to fasting, exercise, and diet can vary widely. It’s also unclear which specific lifestyle changes caused particular effects, as multiple aspects were altered simultaneously.

    Caution is also warranted regarding the biological age estimate. A 47-year-old with an apparent biological age of 32 doesn’t mean they have literally reversed 15 years of aging. These estimates depend on the measurement methods and models used, and their predictive validity for long-term health still requires validation.

    Furthermore, Ho’s fasting and exercise regimen was quite intensive. Regularly fasting for 20 hours, doing 48-hour fasts, and exercising for 90 minutes every day may not be safe or suitable for everyone—particularly those with certain health conditions, older adults, pregnant women, or individuals with eating disorders. The study should not be viewed as a blueprint for everyone.

    Overall, DELTA showcases the potential of highly personalized health tracking rather than proving an anti-aging breakthrough. Its main contribution is illustrating that health is dynamic, and recovery from various challenges can reveal hidden aspects of well-being beyond routine checkups.

    Larger, more diverse studies will be necessary to determine if these measurements can reliably predict healthier aging or extend lifespan.

    For those interested in wellness, reviewing research on how ultra-processed foods, red meat, and seafood impact longevity can be valuable, along with studies suggesting that olive oil and vitamin D may support healthy aging.

  • ‘Artery-on-a-Chip’ May Foretell Stroke Risk Early

    ‘Artery-on-a-Chip’ May Foretell Stroke Risk Early

    Doctors have long found it challenging to accurately predict who might experience an ischemic stroke. Sometimes, individuals with only minor artery narrowing suddenly develop dangerous blood clots, while others with more extensive disease show no symptoms at all.

    A recent study indicates that examining the unique shape of a person’s arteries could offer much clearer insights. Researchers at the University of Sydney have created a miniature laboratory device called an artery-on-a-chip, which serves as a physical replica of a patient’s artery. Their research, published in the journal Cell Biomaterials, shows that this technology aims to precisely mimic an individual’s blood vessels and the flow of blood through them.

    An ischemic stroke occurs when blood flow to part of the brain is blocked, typically by a blood clot. Without oxygen, brain cells begin to die in just minutes. Because rapid intervention is crucial, medical professionals are actively seeking improved ways to identify those at highest risk before a stroke happens.

    Presently, many assessment methods focus solely on the degree of artery narrowing. Yet, findings reveal that some patients with moderate narrowing still suffer strokes, whereas others with severe narrowing remain stable. Clearly, narrowing alone doesn’t provide the full picture.

    To explore this further, the researchers reconstructed carotid arteries from six patients with varying levels of artery disease—the carotid arteries being the main vessels in the neck that supply blood to the brain. They employed advanced computer modeling to analyze exactly how blood flows through each artery.

    The team found that arteries with similar levels of narrowing often exhibited drastically different blood flow patterns. Minor differences in the three-dimensional structure of the arteries created regions where blood flow was slower or turbulence occurred. These variations influenced clot formation and the likelihood of clots breaking free.

    Recreating each artery within a small chip, the scientists used cells resembling those lining real blood vessels. They also introduced tiny injuries to simulate damage common in diseased arteries. The clotting responses varied significantly between patients, highlighting how individual artery structure may strongly impact stroke risk.

    Lead researcher Professor Lining Arnold Ju explained that the project was driven by the need to better identify patients who seem to be at low risk but still suffer severe or fatal strokes. The study’s first author, Yunduo Charles Zhao, shared that his motivation deepened after losing his grandmother to a stroke during his doctoral studies, fueling his focus on improving stroke prediction.

    The team hopes that this new platform will enable scientists to test medications aimed at reducing clot formation, ultimately guiding doctors to tailor treatments based on each patient’s artery anatomy.

    Currently, patient recruitment for a clinical trial is underway to assess how well this technology predicts stroke risk in real-world clinical settings. Researchers also see potential applications for studying other vascular conditions, such as deep vein thrombosis, aneurysms, and peripheral artery disease.

    This early-stage research marks a significant step toward personalized stroke prevention. While larger clinical trials are necessary, the technology has the potential to help doctors identify high-risk individuals sooner, allowing for more targeted preventative therapies before a stroke occurs. The study was published in Cell Biomaterials.

    If stroke prevention interests you, explore studies suggesting that diets rich in flavonoids might lower stroke risk, and that the MIND diet could slow cognitive decline after a stroke.

    Additionally, recent research indicates antioxidants may help reduce dementia risk, and beverages like tea and coffee could potentially decrease the likelihood of stroke and dementia.

    Copyright © 2026 Knowridge Science Report. All rights reserved.

  • New mRNA Vaccine May Reduce Skin Cancer Mortality

    New mRNA Vaccine May Reduce Skin Cancer Mortality

    Scientists have reported promising long-term results from a study combining a personalized mRNA vaccine with a leading immunotherapy drug to help prevent melanoma from returning.

    The research, conducted by investigators at NYU Langone Health and its Perlmutter Cancer Center, indicates that this treatment approach could significantly improve survival rates and lower the risk of cancer metastasis. The findings were shared at the 2026 American Society of Clinical Oncology meeting and published in the Journal of Clinical Oncology.

    Cancer therapies have seen dramatic changes over recent years. Once, options were primarily limited to surgery, chemotherapy, and radiation. Today, immunotherapy has become a cornerstone treatment, leveraging the body’s own immune system to fight cancer more effectively.

    While immunotherapy has revolutionized care for many melanoma patients, its effectiveness varies. Some tumors develop ways to evade immune detection and may return months or even years after initial treatment.

    To address this challenge, researchers developed a personalized vaccine called intismeran. Unlike traditional vaccines designed to prevent certain infections, this vaccine is tailored for each patient.

    Researchers analyze a patient’s tumor tissue after surgery to identify dozens of abnormal proteins known as neoantigens. These neoantigens act like unique fingerprints that differentiate cancer cells from healthy ones.

    Using mRNA technology, scientists then create a custom vaccine that contains instructions targeting these specific tumor markers. When injected, the vaccine trains the immune system to recognize and attack cells displaying these markers. The objective is to bolster immune cells to eliminate any remaining melanoma cells before they can form new tumors.

    This vaccine was tested alongside pembrolizumab, a widely used immunotherapy drug that works by blocking a protein called PD-1 — a protein cancer cells often exploit to hide from immune detection. By inhibiting PD-1, pembrolizumab helps restore the immune system’s ability to identify and attack cancer.

    From 2019 to 2021, the clinical trial enrolled patients in the U.S. and Australia. All had previously undergone surgery to remove melanoma. Researchers compared the outcomes of patients who received both the personalized vaccine and pembrolizumab with those who received only pembrolizumab.

    After five years, the results showed a clear advantage for the combination group. Nearly 70% remained cancer-free, while less than 50% of those treated with just pembrolizumab achieved the same. The combined approach cut the risk of recurrence or death by nearly half.

    Additionally, patients receiving the combined therapy were less likely to experience the spread of melanoma to distant organs—an essential factor since metastatic melanoma is much harder to treat and accounts for many cancer-related deaths. Survival rates were also notably higher among recipients of the personalized vaccine.

    These findings provide some of the strongest evidence to date that mRNA technology can be effectively used against cancer.

    While mRNA gained widespread attention during the pandemic, its potential in oncology has been under investigation for years. One major advantage of mRNA is its adaptability—scientists can quickly design treatments tailored to the genetic makeup of an individual’s tumor.

    This personalized approach is especially promising for cancers like melanoma, which often harbor numerous mutations. The more unique markers a tumor has, the more targets the immune system can be trained to recognize and attack.

    The safety profile observed in the study was encouraging, with most side effects being manageable, including fatigue, chills, and injection site discomfort. No serious safety issues emerged during the trial.

    Despite these positive results, experts emphasize that further research is necessary. Since this was a Phase IIb trial, larger studies are needed before the treatment can become a standard option. Fortunately, a Phase III international trial is already in progress, which will help confirm the vaccine’s effectiveness on a broader scale.

    Scientifically, these results are highly significant. They suggest that personalized vaccines could enhance existing immunotherapy treatments rather than replace them. This combined strategy might serve as a model for future cancer therapies.

    However, given the small size of this study, cautious interpretation is advised until larger trials are completed. If future research confirms these findings, personalized mRNA vaccines could represent a major breakthrough in cancer treatment—potentially applicable to many different types of cancer.

    For those interested in skin health, studies have linked fish consumption with a higher risk of skin cancer, while Vitamin B3 may help prevent skin cancers. Additional research discusses how vegetable oils might contribute to cancer spread and how vitamin D could assist in treating skin inflammation.

    Source: NYU Langone Health

  • Why Sleep Apnea Patients See More Benefits from This Popular Weight Loss Drug

    Why Sleep Apnea Patients See More Benefits from This Popular Weight Loss Drug

    Research indicates that certain individuals with obstructive sleep apnea and obesity may experience significantly greater benefits from the GLP-1 medication tirzepatide compared to others. These insights could assist physicians in better predicting which patients are most likely to see improvements and who might still require supplementary treatments for sleep apnea.

    Presented at the 2026 ATS International Conference, this study focused on obstructive sleep apnea—a condition characterized by repeated interruptions in breathing during sleep. This affliction affects millions globally, resulting from the relaxation of muscles and tissues around the airway, which narrows or blocks airflow. The resulting breathing pauses can occur multiple times throughout the night.

    Common symptoms include loud snoring, poor sleep quality, morning headaches, daytime fatigue, concentration difficulties, and mood disturbances. If left untreated, severe sleep apnea can elevate the risk of hypertension, cardiovascular disease, stroke, diabetes, and premature mortality.

    Obesity is among the most significant risk factors for sleep apnea, as excess fat around the neck and throat can constrict the airway and make it more prone to collapse during sleep. Recently, GLP-1 medications such as tirzepatide have gained popularity for managing obesity and type 2 diabetes, as they help control appetite and blood sugar, often resulting in notable weight loss.

    Evidence suggests that weight reduction from these drugs may also alleviate sleep apnea symptoms. However, clinicians observed that some patients experience dramatic improvements, while others show only modest progress. To explore these differences, researchers led by Dr. Scott Sands at Brigham and Women’s Hospital and Harvard Medical School analyzed data from a prior clinical trial involving tirzepatide in patients with both obesity and sleep apnea.

    They identified a subgroup labeled “strong responders,” who showed nearly twice the improvement in sleep apnea severity compared to other patients. Further analysis revealed that these responders were generally younger, with less severe obesity, and displayed particular breathing and airway characteristics tied to sleep apnea’s biological basis.

    One key factor was greater airway collapsibility—the tendency of the upper airway to close during sleep. Another involved breathing control instability, termed high loop gain, which describes how sensitive the breathing system is to changes in oxygen and carbon dioxide levels. High loop gain can cause breathing to become unstable and overreactive, intensifying sleep apnea. Additionally, strong responders were more likely to wake up when airflow restriction occurred.

    Surprisingly, high loop gain predicted better outcomes with tirzepatide treatment. Subsequent analysis suggested that the medication might improve not only weight and airway stability but also the underlying breathing instability. This implies tirzepatide could target multiple causes of sleep apnea concurrently.

    Dr. Sands explains that these findings could eventually enable more personalized treatment strategies for patients considering GLP-1 therapies. Currently, clinicians mainly rely on average results from clinical trials—typically, tirzepatide reduces sleep apnea severity by about 50% compared to a placebo. However, the new data indicates some patients may see much greater improvements, while others might still require devices like CPAP.

    Continuous positive airway pressure (CPAP), which keeps the airway open during sleep using pressurized air delivered through a mask, remains the standard treatment. While effective, compliance can be an issue for some. The potential for medications like tirzepatide to lessen the severity of sleep apnea has sparked significant interest among sleep specialists and obesity researchers.

    This shift aligns with broader trends toward personalized medicine, emphasizing an understanding of individual biological differences that influence responses to treatment. Future research aims to compare outcomes across various weight-loss approaches—including medications, lifestyle changes, and surgical options—to better match patients with the most effective therapies for their specific form of sleep apnea.

    For those focused on weight loss, recent studies suggest that hop extract might help reduce belly fat in overweight individuals, and early time-restricted eating could support weight loss efforts. Additional updates include research on simple pathways to weight reduction and non-invasive treatments for obesity and diabetes.

    Source: Brigham and Women’s Hospital.

  • Are Diabetes and Weight-Loss Drugs a Good Match?

    Are Diabetes and Weight-Loss Drugs a Good Match?

    Credit: Unsplash+.


    Millions worldwide are affected by type 2 diabetes, and recent international research, led by Adelaide University, the University of Oxford, ETH Zurich, and Stanford University, reveals that one in ten individuals may not respond to common diabetes medications.

    The study uncovered genetic differences present in about ten percent of the population that could hinder the effectiveness of GLP-1 receptor drugs, such as Ozempic.

    This research emphasizes the importance of personalized medicine when prescribing these popular medications, which are also employed for weight loss.

    “Recent advancements in treating diabetes and obesity have been driven by widespread use of GLP-1 based therapies like Ozempic,” said lead researcher Dr. Mahesh Umapathysivam from Adelaide University’s Centre of Research Excellence: Translating Nutritional Science to Good Health.

    “However, not all patients respond equally well,” he added. “Understanding why, and being able to predict who will benefit or not, will help us tailor treatments more effectively to individual patients.”

    The findings, published in Genome Medicine, stem from numerous human and animal trials examining how specific gene variants in the PAM gene increase the risk of developing type 2 diabetes.

    This study builds on previous research showing that the PAM gene worsens diabetes risk by reducing insulin production and altering hormone structures, including the GLP-1 hormone responsible for blood sugar regulation.

    In this latest research, scientists showed that variations in the PAM gene made the enzyme less effective, leading to higher levels of natural GLP-1 but diminishing the hormone’s positive influence on blood sugar. This indicates a form of resistance to GLP-1 in individuals with these genetic traits.

    Further investigation revealed that this genetic resistance impacts how the body responds to GLP-1 medications. For carriers of specific PAM gene variants, the medications’ ability to lower blood glucose was reduced by as much as 44% over six months.

    Only about 11% of those with the more harmful PAM variant managed to reach recommended blood sugar levels while on these drugs, compared to roughly 25% of individuals without the mutation.

    “Our study offers critical clinical evidence showing that certain gene variants make some people more prone to diabetes and less responsive to GLP-1 therapies,” said Dr. Umapathysivam. “As we identify more genetic markers predicting treatment response, we can combine this data to select the most effective medication for each patient.”

    GLP-1 medications like Ozempic are typically injectable treatments that help control blood sugar by stimulating insulin production and suppressing appetite.

    “Type 2 diabetes remains one of the leading causes of health complications and death worldwide. Despite the variety of available treatments, only half of all patients meet the target blood glucose levels,” noted Dr. Umapathysivam. “This underscores the need for more personalized treatment strategies to improve patient outcomes.”

    The ongoing research, supported by Diabetes Australia, aims to expand these findings.

    “We hope this work will pave the way for future genetic testing panels that identify the best medications for individual patients, thereby enhancing diabetes management and reducing adverse effects,” said Dr. Umapathysivam.


  • Can Vitamin D Help Prevent Diabetes?

    Can Vitamin D Help Prevent Diabetes?

    Prediabetes is a widespread health issue across the United States. It occurs when blood sugar levels are elevated but not high enough to be classified as diabetes. Many individuals with prediabetes experience no symptoms, so they might be unaware of their condition.

    Over time, prediabetes can progress to type 2 diabetes, a serious illness that can impact the heart, kidneys, eyes, and nerves. A recent study offers an optimistic perspective: it indicates that vitamin D, an affordable and commonly available supplement, may help lower the risk of developing diabetes. However, this potential benefit appears to vary based on a person’s genetic makeup.

    The research was published in JAMA Network Open and conducted by scientists at Tufts University, led by Bess Dawson-Hughes. They analyzed data from the D2d trial, involving over 2,000 U.S. adults with prediabetes. In the original trial, participants received either a high dose of vitamin D—4,000 units daily, significantly above typical daily recommendations—or a placebo. The aim was to evaluate whether vitamin D could prevent the onset of diabetes.

    Initially, the overall results were inconclusive; vitamin D did not significantly reduce diabetes risk across the entire group. But the researchers dug deeper. They questioned whether specific subgroups might benefit more.

    By examining genetic information from the participants, particularly focusing on a gene linked to the vitamin D receptor—a “lock” that vitamin D must fit into to activate its functions—they identified notable differences. This receptor influences how vitamin D helps regulate processes like blood sugar management.

    Findings showed that about 30% of the participants had a particular gene variant called the AA type. These individuals did not experience any protection from vitamin D supplementation concerning diabetes risk. Conversely, those with other variants (AC or CC) did see benefits—about 19% lower risk of developing diabetes when taking vitamin D compared to placebo.

    This discovery emphasizes that a simple supplement might be highly effective for some, but not for others, supporting the growing movement toward personalized medicine. Instead of generic treatments, future healthcare could involve genetic testing to tailor preventive strategies.

    The study also sheds light on why previous research on vitamin D’s role in preventing diabetes has yielded mixed results—benefits seem to depend on individual genetics. Nonetheless, experts warn against self-medicating with high-dose vitamin D, as excessive intake can pose health risks, including bone issues and falls in older adults. Current guidelines recommend much lower daily doses for most people.

    While the study’s strengths include its large size, rigorous design, and genetic analysis, it also has limitations. Additional studies are needed to confirm these findings across diverse populations and to understand the long-term effects of high-dose vitamin D.

    Overall, this research marks an important step toward more personalized healthcare, suggesting that genetic testing could identify who might benefit most from vitamin D to delay or prevent diabetes.

    For those interested in nutrition, it’s worth exploring the risks of vitamin D deficiency and how the Mediterranean diet may help preserve brain health in older adults. Stay informed with recent studies on natural ways to lower high blood pressure and simple dietary changes to manage type 2 diabetes.

  • Innovative Wearable Sensor Detects Organ Failure at Early Stage

    Innovative Wearable Sensor Detects Organ Failure at Early Stage

    Credit: Unsplash+

    For decades, physicians have depended on blood tests to assess how the body functions. These tests reveal whether organs like the liver and kidneys are healthy and if medications are working as intended. However, they only capture data at a single point in time, which can cause important changes to be overlooked.

    A recent study from researchers at the University of California, Los Angeles, proposes a different strategy. Published in Science Translational Medicine, the research introduces a compact wearable device designed to continuously monitor vital substances through the skin.

    The device operates using tiny structures called microneedles—so small that they sit just beneath the skin’s surface with minimal discomfort. These microneedles are engineered to detect specific molecules by generating an electrical signal when they come into contact with them.

    What makes this sensor innovative is its enhanced design. The researchers developed a surface dotted with numerous tiny openings, significantly boosting its ability to detect molecules. This improvement grants it much higher sensitivity compared to older models and allows it to function reliably for several days without losing accuracy.

    In experiments, the team tested the device on animals, tracking how two different drugs moved through the body over time. One drug was processed by the liver, while the other was cleared by the kidneys. Monitoring these substances’ levels provided insights into how well these organs were functioning. If the drugs lingered longer than expected, it suggested potential organ impairment.

    A key finding was that the sensor could identify early warning signs of organ issues before conventional tests could. For instance, it detected early alterations related to kidney damage even when standard blood tests remained normal.

    This early detection capability is highly valuable in medical care, as it could enable healthcare providers to intervene sooner, adjusting treatments to prevent serious complications. This is critical with potent medications like chemotherapy drugs and antibiotics, which can harm organs if not carefully monitored.

    The technology also shows promise for future development. One patch could potentially host multiple sensors, each tracking different molecules to provide a comprehensive, real-time health overview.

    Another benefit lies in cost-efficiency. The device is designed to be produced at a relatively low cost, potentially making this continuous monitoring approach accessible to more people.

    Nevertheless, challenges remain. Since the study was conducted on animals, additional testing in humans is required. Researchers will also need to ensure the device remains accurate and safe during prolonged use.

    Overall, this research signifies a major shift in healthcare delivery. Instead of sporadic testing, doctors could soon continuously monitor patients, enabling earlier detection of health issues, more informed treatment decisions, and better outcomes.

    In summary, the study illustrates how emerging technology can push medicine toward a more personalized approach. Providing doctors with a clearer, ongoing view inside the body may help prevent harm and enhance treatment effectiveness. While further research is needed, the potential benefits are considerable.

    If you’re interested in health topics, consider looking into studies suggesting vitamin D might decrease the risk of autoimmune diseases or that some anti-inflammatory drugs could inhibit cancer spread.

    For additional health updates, explore recent research on which medications pose the greatest risk to your liver or how certain drugs can boost your immune system to combat cancer more effectively.